Peer to Peer

Addressing Patient Concerns About Treatment Safety Data

Author and Disclosure Information

In this edition of the “Peer to Peer” audiocast series, Dr. Vincent DeLeo speaks with Dr. Steven Feldman about treatment compliance and addressing patient concerns about treatment safety data. They discuss strategies for reassuring patients about risks associated with biologics for psoriasis and other drugs, particularly risks patients may read about on the Internet.


 

Recommended Reading

Infliximab biosimilar posts mostly reassuring data in Norway’s NOR-SWITCH study
MDedge Dermatology
Pediatric psoriasis linked to multiple psychiatric comorbidities
MDedge Dermatology
Update on New Drugs in Dermatology
MDedge Dermatology
VIDEO: Tune in to psoriasis patients’ quality of life
MDedge Dermatology
Fighting back against psoriasis bullies
MDedge Dermatology
Study finds etanercept biosimilar safe and effective in patients with severe plaque psoriasis
MDedge Dermatology
Spot Psoriatic Arthritis Early in Psoriasis Patients
MDedge Dermatology
Psoriasis Treatment Considerations in Military Patients: Unique Patients, Unique Drugs
MDedge Dermatology
Psoriasis and Internal Disease: Report From the Mount Sinai Winter Symposium
MDedge Dermatology
Latest ixekizumab safety data called ‘very reassuring’
MDedge Dermatology

Related Articles